Frankfurt
20.12.24
09:19 Uhr
0,081 Euro
+0,020
+32,57 %
+32,57 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.11. | AlzeCure Pharma: AlzeCure to Present at the Pharma Outsourcing Conference in Stockholm | 186 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / November 27, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops small molecule drugs for... ► Artikel lesen | |
| 26.11. | AlzeCure Pharma to Present at Redeye Life Science Day on December 3 | 163 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / November 26, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 20.11. | AlzeCure Pharma to Present at Stora Aktiedagarna in Stockholm | 261 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / November 20, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 11.11. | AlzeCure Pharma: AlzeCure Publishes its Interim Report for January - September 2024 | 637 | ACCESSWIRE | STOCKHOLM, SE / ACCESSWIRE / November 11, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its interim report for the period January - September... ► Artikel lesen | |
| ALZECURE PHARMA Aktie jetzt für 0€ handeln | |||||
| 30.10. | AlzeCure Pharma: AlzeCure Presents New Anti-Inflammatory Data with NeuroRestore ACD856 at the Alzheimer's Conference CTAD | 411 | ACCESSWIRE | STOCKHOLM, SE / ACCESSWIRE / October 30, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting... ► Artikel lesen | |
| 28.10. | AlzeCure Pharma: AlzeCure Presents New Positive Data for the TrkA-NAM Pain Project Against Osteoarthritis | 212 | ACCESSWIRE | STOCKHOLM, SE / ACCESSWIRE / October 28, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for CNS diseases... ► Artikel lesen | |
| 24.10. | AlzeCure Pharma: AlzeCure to Present at the International Partnering Conference Bioscience 2024 on November 7 | 265 | ACCESSWIRE | STOCKHOLM, SE / ACCESSWIRE / October 24, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 17.10. | AlzeCure Pharma's CEO Martin Jönsson to present at Redeye's Neurology Day | 225 | ACCESSWIRE | STOCKHOLM, SE / ACCESSWIRE / October 17, 2024 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 10.10. | AlzeCure Pharma Broadcasts Live Event About the Phase II Candidate ACD440 Against Neuropathic Pain | 242 | ACCESSWIRE | STOCKHOLM, SE / ACCESSWIRE / October 10, 2024 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 02.10. | AlzeCure's abstract on ACD856's effects to be presented at Alzheimer's conference | 5 | PharmaTimes | ||
| 01.10. | AlzeCure Pharma: AlzeCure's Abstract on ACD856's Anti-inflammatory Effects to be Presented at a Leading Alzheimer's Conference | 238 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / October 1, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 26.08. | AlzeCure Pharma: AlzeCure Publishes its Interim Report for January - June 2024 | 422 | ACCESSWIRE | STOCKHOLM, SE / ACCESSWIRE / August 26, 2024 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that its interim report for the period January - June... ► Artikel lesen | |
| 13.08. | AlzeCure Pharma: New Scientific Article on NeuroRestore ACD856 and its Improved Cognition and Disease Modification of Alzheimer's Disease | 638 | ACCESSWIRE | STOCKHOLM, SE / ACCESSWIRE / August 13, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting... ► Artikel lesen | |
| 07.08. | AlzeCure Pharma: New Results from AlzeCure's Pain Project TrkA-NAM Presented at the Pain Conference IASP 2024 | 277 | ACCESSWIRE | STOCKHOLM, SE / ACCESSWIRE / August 07, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting... ► Artikel lesen | |
| 13.06. | AlzeCure Pharma: New Scientific Article Published on Positive Clinical Results with Painless ACD440 Against Neuropathic Pain | 362 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / June 13, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 28.05. | Nasdaq Stockholm AB: New last day of trading in paid subscription shares (BTA) of AlzeCure Pharma AB (publ) | 214 | GlobeNewswire | At the request of AlzeCure Pharma AB (publ), the last trading day in AlzeCure
Pharma AB (publ)'s paid subscription units will be changed from May 30, 2024 to
May 31, 2024.
Short name: ALZCUR BTA... ► Artikel lesen | |
| 15.05. | AlzeCure Pharma: Eli Lilly's and AstraZeneca's Former Head of Research Dr. Jan Lundberg Elected as a New Board Member | 557 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / May 15, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB, a pharmaceutical company that develops candidate drugs for CNS diseases, focusing on Alzheimer's... ► Artikel lesen | |
| 14.05. | Communiqué from the Annual General Meeting of AlzeCure Pharma on 14 May 2024 | 661 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) Today, 14 May 2024, the annual general meeting was held in AlzeCure Pharma AB (publ) (the "Company"). Below is a... ► Artikel lesen | |
| 13.05. | AlzeCure Pharma: AlzeCure Reports Anti-Inflammatory Effects with NeuroRestore ACD856 with Relevance to Alzheimer's Leading to New Patent Application | 280 | ACCESSWIRE | STOCKHOLM, SWEDEN / ACCESSWIRE / May 13, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting... ► Artikel lesen | |
| 30.04. | Nasdaq Stockholm AB: Listing of subscription rights and paid subscription shares of AlzeCure Pharma AB | 397 | GlobeNewswire | With effect from May 02, 2024, the subscription rights in AlzeCure Pharma AB
will be traded on First North Growth Market. Trading will continue up until and
including May 14, 2024.
Instrument: Subscription... ► Artikel lesen |
Seite:
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS | 379,85 | -0,25 % | Massive Kursverluste für die Aktie von Vertex Pharmaceuticals (379,50 €) | Am US-amerikanischen Aktienmarkt fällt aktuell die Vertex Pharmaceuticals-Aktie negativ auf. Der Kurs der Aktie sackt kräftig ab. Mit einem Abschlag von 12,07 Prozent gehört heute das Wertpapier von... ► Artikel lesen | |
| VIATRIS | 11,970 | -0,33 % | Kaum Impulse für die Viatris-Aktie (12,0044 €) | Der Kurs der dem Anteilsschein von Viatris kommt kaum von der Stelle. Der jüngste Kurs betrug 12,60 US-Dollar. Der Kurs der Aktie von Viatris zeigt sich zur Stunde kaum verändert im Vergleich zu der... ► Artikel lesen | |
| OPKO HEALTH | 1,477 | -0,28 % | OPKO Health, Inc.: ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program | Brings total awards from BARDA to $110 million for development of broad SARS-CoV-2 and Influenza multispecifics, with potential funding of up to $205 million if all options are executedDevelopment... ► Artikel lesen | |
| JAGUAR HEALTH | 0,929 | +6,44 % | Jaguar Health, Inc.: Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications | Magdalena to explore coca leaf's possible therapeutic benefit for treatment of potentially ADHD or other neuropsychiatric indicationsThe import was conducted in collaboration with the government of... ► Artikel lesen | |
| ALTIMMUNE | 8,240 | +3,97 % | Altimmune, Inc: Altimmune Added to Nasdaq Biotechnology Index | GAITHERSBURG, Md., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will be added to the Nasdaq Biotechnology Index... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 0,875 | +0,81 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia | - Study Reaches Pre-Specified Threshold of 60 Events (Deaths) Initiating the Interim Analysis - - REGAL Independent Data Monitoring Committee to Perform Interim Analysis in January 2025 - - Company... ► Artikel lesen | |
| AURINIA PHARMACEUTICALS | 8,826 | +1,87 % | Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS Growth and AUR200 Development | ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the third quarter and nine months... ► Artikel lesen | |
| KIORA PHARMACEUTICALS | 3,270 | +2,51 % | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies | Encinitas, California--(Newsfile Corp. - November 8, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced third quarter 2024 financial results and provided... ► Artikel lesen | |
| LIPOCINE | 4,800 | +2,56 % | Lipocine Inc.: FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis | SALT LAKE CITY, Dec. 17, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment... ► Artikel lesen | |
| PHOTOCURE | 5,260 | +5,62 % | Photocure ASA: Initiation of a share buyback | ||
| ACLARIS THERAPEUTICS | 2,709 | +3,28 % | Aclaris Therapeutics, Inc.: Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WAYNE, Pa., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS)(the "Company" or "Aclaris"), a clinical-stage biopharmaceutical company focused on developing novel drug candidates... ► Artikel lesen | |
| EUROBIO SCIENTIFIC | 25,150 | +6,57 % | Eurobio Scientific: EB Development obtains a significant majority of the capital with 88.9% held at the end of the Reopened Offer to continue its development with NextStage AM and IK Partners | Eurobio Scientific: EB Development obtains a significant majority of the capital with 88.9% held at the end of the Reopened Offer to continue its development with NextStage AM and IK Partners Paris... ► Artikel lesen | |
| SOLID BIOSCIENCES | 4,150 | +3,62 % | Solid Biosciences stock hits 52-week low at $4.61 | ||
| MEDICURE | 0,575 | -0,86 % | Medicure, Inc.: Medicure Reports Financial Results For Quarter Ended September 30, 2024 | WINNIPEG, MB / ACCESSWIRE / November 25, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals... ► Artikel lesen | |
| BAYER | 18,936 | +0,35 % | Dividendenperlen: Nicht Super Micro & Bayer: 3 Wachstums-Dividendenaktien für 2025 & darüber hinaus | Das aktuelle Börsenjahr nähert sich dem Ende. Welche Aktien könnten zukünftig gut abschneiden? 2024 war trotz geopolitischer Konflikte, Rezessionstendenzen und politischer Turbulenzen bisher ein sehr... ► Artikel lesen |
Das Unternehmen ALZECURE PHARMA AB kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell +32,57 % bei einem Aktienkurs von 0,081 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALZECURE PHARMA AB finden Sie auf Wallstreet Online.
